A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 202 participants.

Also called NCT05036135

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 202 participants (enrolled count) (from the registry)
Sponsor
Aerovate Therapeutics (from the registry)
Registry
  • NCT NCT05036135
Other papers using this trial's data
  • Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension American journal of respiratory and critical care medicine, 2026-04-01 DOI, PubMed 41738079

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, France, Germany, Greece, Israel, Italy, Latvia, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05036135. Randomized; quadruple masking; primary purpose treatment. Start 2021-12-02 (actual); primary completion 2024-08-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
Acronym
IMPAHCT
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
AV-101
Intervention (Drug)
Placebo
Lead sponsor
Aerovate Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct05036135
Content hash
59b0cb483390bdd3c91531ccdefac888ddb19ab41e593b9188dc62b8774cccb3